Health
Clinical trial shows five-year outcomes of CAR T-cell therapy for non-Hodgkin lymphomas – News-Medical.Net
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the…
A significant number of non-Hodgkin lymphoma (NHL) patients in a Penn Medicine-initiated clinical trial continue to be in remission five years after receiving the chimeric antigen receptor (CAR) T cell therapy Kymriah™, researchers in Penn’s Abramson Cancer Center reported today in the New England Journal of Medicine. The findings represent the longest follow-up, published data to date for CAR T cell therapies approved by the U.S. Food and Drug Administration for the treatment of relapsed or refractory…
-
Noosa News24 hours agoNew self-serve style chip shop, Chip ‘n’ Mix, in Noosa becomes an instant obsession
-
General23 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
General23 hours agoAsia stocks plunge, HK suffers steepest fall since 1997
-
Business15 hours ago2 Low Cost Active ASX ETFs to consider